Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection

Fig. 4

Specific anti-tumor immunity elicited by MCMV-based vaccine vectors is essential for protection. a TC-1 tumor outgrowth of unvaccinated mice and of mice previously vaccinated with MCMV-IE2-E7 or MCMV-IE2-OVA via the IP route. CD8 depleting antibody was given in the group of mice vaccinated with MCMV-IE2-E7 via IP starting 4 days before tumor challenge. The number of tumor-free/total mice is indicated in each graph. Data was pooled from two independent experiments. b MC38-OVA tumor outgrowth of unvaccinated mice and of mice previously vaccinated with MCMV-IE2-E7 or MCMV-IE2-OVA via the IP route. The number of tumor-free/total mice is indicated in each graph. Data are representative of two independent experiments with similar results. c and d Representative histograms of CTL-mediated killing responses induced by MCMV-IE2-E7 (c) or MCMV-IE2-OVA (d). Mice were vaccinated with 5 × 105 PFU MCMV-IE2-E7 (c) or MCMV-IE2-OVA (d) via SC. After 69 days, splenocytes from naïve mouse were pulsed with specific peptide; E749–57 (c) or OVA257–264 (d) or unspecific peptide and labelled with high and low concentrations of CFSE, respectively. Then, cells were adoptively transferred to the MCMV vaccinated mice or naïve mice as control. One day later, spleens of the mice were analyzed for the percentage of killing as described in materials and methods

Back to article page